Thiogenesis Therapeutics (TTI) Stock Overview
A clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TTI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Thiogenesis Therapeutics, Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.61 |
| 52 Week High | CA$0.88 |
| 52 Week Low | CA$0.44 |
| Beta | 0.52 |
| 1 Month Change | 17.31% |
| 3 Month Change | -6.15% |
| 1 Year Change | 8.93% |
| 3 Year Change | -11.59% |
| 5 Year Change | n/a |
| Change since IPO | 22.00% |
Recent News & Updates
We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Apr 16
Is Thiogenesis Therapeutics (CVE:TTI) In A Good Position To Invest In Growth?
Jan 01Recent updates
We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Apr 16Is Thiogenesis Therapeutics (CVE:TTI) In A Good Position To Invest In Growth?
Jan 01We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
Nov 20We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully
Jul 17Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate
May 01Shareholder Returns
| TTI | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 13.0% | 6.6% | 1.8% |
| 1Y | 8.9% | 29.0% | 40.7% |
Return vs Industry: TTI underperformed the Canadian Biotechs industry which returned 29% over the past year.
Return vs Market: TTI underperformed the Canadian Market which returned 40.7% over the past year.
Price Volatility
| TTI volatility | |
|---|---|
| TTI Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 10.9% |
| 10% most volatile stocks in CA Market | 18.9% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: TTI has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: TTI's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Patrice Rioux | www.thiogenesis.com |
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.
Thiogenesis Therapeutics, Corp. Fundamentals Summary
| TTI fundamental statistics | |
|---|---|
| Market cap | CA$31.62m |
| Earnings (TTM) | -CA$6.82m |
| Revenue (TTM) | n/a |
Is TTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTI income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$6.82m |
| Earnings | -CA$6.82m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/19 00:59 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Thiogenesis Therapeutics, Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bob Pooler | ValuationLAB AG |